1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Materials	_	_	NNS	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	Methods	_	_	NNS	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	search	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	performed	_	_	VBN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	regulatory	_	_	JJ	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	scientific	_	_	JJ	_	_	_	_	_
9	literature	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	identify	_	_	VB	_	_	_	_	_
12	sources	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	clinical	_	_	JJ	_	_	_	_	_
15	data	_	_	NNS	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	used	_	_	VBN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	compare	_	_	VB	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	efficacy	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	safety	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	BRAFi/MEKi	_	_	NNP	_	_	_	_	_
27	combination	_	_	NN	_	_	_	_	_
28	therapies	_	_	NNS	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	treatment	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	BRAF	_	_	NNP	_	_	_	_	_
34	-mutant	_	_	JJ	_	_	_	_	_
35	metastatic	_	_	JJ	_	_	_	_	_
36	melanoma	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	full	_	_	JJ	_	_	_	_	_
3	details	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	literature	_	_	NN	_	_	_	_	_
7	search	_	_	NN	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	outlined	_	_	VBN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	Table	_	_	NNP	_	_	_	_	_
12	S4	_	_	NNP	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Four	_	_	CD	_	_	_	_	_
2	phase	_	_	NN	_	_	_	_	_
3	III	_	_	CD	_	_	_	_	_
4	studies	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	identified	_	_	VBN	_	_	_	_	_
7	:	_	_	:	_	_	_	_	_
8	coBRIM	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	phase	_	_	NN	_	_	_	_	_
12	III	_	_	CD	_	_	_	_	_
13	trial	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	cobimetinib	_	_	NN	_	_	_	_	_
16	plus	_	_	CC	_	_	_	_	_
17	vemurafenib	_	_	NN	_	_	_	_	_
18	versus	_	_	IN	_	_	_	_	_
19	vemurafenib	_	_	NN	_	_	_	_	_
20	monotherapy	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	previously	_	_	RB	_	_	_	_	_
23	untreated	_	_	JJ	_	_	_	_	_
24	patients	_	_	NNS	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	advanced	_	_	JJ	_	_	_	_	_
27	BRAF	_	_	NN	_	_	_	_	_
28	-mutant	_	_	JJ	_	_	_	_	_
29	melanoma	_	_	NN	_	_	_	_	_
30	;	_	_	:	_	_	_	_	_
31	COMBI-d	_	_	NNP	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	a	_	_	DT	_	_	_	_	_
34	phase	_	_	NN	_	_	_	_	_
35	III	_	_	CD	_	_	_	_	_
36	trial	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	dabrafenib	_	_	NN	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	trametinib	_	_	NN	_	_	_	_	_
41	versus	_	_	IN	_	_	_	_	_
42	dabrafenib	_	_	NN	_	_	_	_	_
43	monotherapy	_	_	NN	_	_	_	_	_
44	in	_	_	IN	_	_	_	_	_
45	previously	_	_	RB	_	_	_	_	_
46	untreated	_	_	JJ	_	_	_	_	_
47	patients	_	_	NNS	_	_	_	_	_
48	with	_	_	IN	_	_	_	_	_
49	unresectable	_	_	JJ	_	_	_	_	_
50	stage	_	_	NN	_	_	_	_	_
51	IIIC	_	_	NN	_	_	_	_	_
52	or	_	_	CC	_	_	_	_	_
53	stage	_	_	NN	_	_	_	_	_
54	IV	_	_	NN	_	_	_	_	_
55	melanoma	_	_	NN	_	_	_	_	_
56	with	_	_	IN	_	_	_	_	_
57	a	_	_	DT	_	_	_	_	_
58	BRAF	_	_	NN	_	_	_	_	_
59	V600E	_	_	NN	_	_	_	_	_
60	or	_	_	CC	_	_	_	_	_
61	V600K	_	_	NN	_	_	_	_	_
62	mutation	_	_	NN	_	_	_	_	_
63	;	_	_	:	_	_	_	_	_
64	COMBI-v	_	_	NNP	_	_	_	_	_
65	,	_	_	,	_	_	_	_	_
66	a	_	_	DT	_	_	_	_	_
67	phase	_	_	NN	_	_	_	_	_
68	III	_	_	CD	_	_	_	_	_
69	trial	_	_	NN	_	_	_	_	_
70	of	_	_	IN	_	_	_	_	_
71	dabrafenib	_	_	NN	_	_	_	_	_
72	plus	_	_	CC	_	_	_	_	_
73	trametinib	_	_	NN	_	_	_	_	_
74	versus	_	_	IN	_	_	_	_	_
75	vemurafenib	_	_	NN	_	_	_	_	_
76	monotherapy	_	_	NN	_	_	_	_	_
77	in	_	_	IN	_	_	_	_	_
78	previously	_	_	RB	_	_	_	_	_
79	untreated	_	_	JJ	_	_	_	_	_
80	patients	_	_	NNS	_	_	_	_	_
81	with	_	_	IN	_	_	_	_	_
82	unresectable	_	_	JJ	_	_	_	_	_
83	stage	_	_	NN	_	_	_	_	_
84	IIIC	_	_	NN	_	_	_	_	_
85	or	_	_	CC	_	_	_	_	_
86	IV	_	_	NN	_	_	_	_	_
87	melanoma	_	_	NN	_	_	_	_	_
88	with	_	_	IN	_	_	_	_	_
89	BRAF	_	_	NN	_	_	_	_	_
90	mutation	_	_	NN	_	_	_	_	_
91	;	_	_	:	_	_	_	_	_
92	and	_	_	CC	_	_	_	_	_
93	COLUMBUS	_	_	NNP	_	_	_	_	_
94	Part	_	_	NN	_	_	_	_	_
95	1	_	_	CD	_	_	_	_	_
96	,	_	_	,	_	_	_	_	_
97	a	_	_	DT	_	_	_	_	_
98	phase	_	_	NN	_	_	_	_	_
99	III	_	_	CD	_	_	_	_	_
100	trial	_	_	NN	_	_	_	_	_
101	of	_	_	IN	_	_	_	_	_
102	encorafenib	_	_	NN	_	_	_	_	_
103	plus	_	_	CC	_	_	_	_	_
104	binimetinib	_	_	NN	_	_	_	_	_
105	versus	_	_	IN	_	_	_	_	_
106	vemurafenib	_	_	NN	_	_	_	_	_
107	or	_	_	CC	_	_	_	_	_
108	encorafenib	_	_	NN	_	_	_	_	_
109	monotherapy	_	_	NN	_	_	_	_	_
110	in	_	_	IN	_	_	_	_	_
111	patients	_	_	NNS	_	_	_	_	_
112	with	_	_	IN	_	_	_	_	_
113	BRAF	_	_	NNP	_	_	_	_	_
114	-mutant	_	_	JJ	_	_	_	_	_
115	melanoma	_	_	NN	_	_	_	_	_
116	.	_	_	.	_	_	_	_	_


1	Three	_	_	CD	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	identified	_	_	VBN	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	coBRIM	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	COMBI-v	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	COLUMBUS	_	_	NNP	_	_	_	_	_
13	Part	_	_	NNP	_	_	_	_	_
14	1	_	_	CD	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	had	_	_	VBD	_	_	_	_	_
18	vemurafenib	_	_	NN	_	_	_	_	_
19	960	_	_	CD	_	_	_	_	_
20	mg	_	_	NN	_	_	_	_	_
21	twice	_	_	RB	_	_	_	_	_
22	daily	_	_	RB	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	BID	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	as	_	_	IN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	control	_	_	NN	_	_	_	_	_
29	arm	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	were	_	_	VBD	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	chief	_	_	JJ	_	_	_	_	_
35	sources	_	_	NNS	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	data	_	_	NNS	_	_	_	_	_
38	for	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	comparisons	_	_	NNS	_	_	_	_	_
41	presented	_	_	VBN	_	_	_	_	_
42	here	_	_	RB	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	COMBI-d	_	_	NNP	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	identified	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	part	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	initial	_	_	JJ	_	_	_	_	_
11	literature	_	_	NN	_	_	_	_	_
12	search	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	it	_	_	PRP	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	not	_	_	RB	_	_	_	_	_
17	included	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	efficacy	_	_	NN	_	_	_	_	_
21	comparison	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	cross-trial	_	_	JJ	_	_	_	_	_
25	comparison	_	_	NN	_	_	_	_	_
26	due	_	_	JJ	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	lack	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	vemurafenib	_	_	NN	_	_	_	_	_
33	control	_	_	NN	_	_	_	_	_
34	arm	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	should	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	noted	_	_	VBN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	however	_	_	RB	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	outcomes	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	COMBI-d	_	_	NNP	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	substantially	_	_	RB	_	_	_	_	_
15	similar	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	those	_	_	DT	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	COMBI-v	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	key	_	_	JJ	_	_	_	_	_
3	design	_	_	NN	_	_	_	_	_
4	features	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	three	_	_	CD	_	_	_	_	_
8	included	_	_	VBN	_	_	_	_	_
9	phase	_	_	NN	_	_	_	_	_
10	III	_	_	NNP	_	_	_	_	_
11	trials	_	_	NNS	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	summarized	_	_	VBN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	Table	_	_	NNP	_	_	_	_	_
16	5	_	_	CD	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	assist	_	_	VB	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	completeness	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	cross-trial	_	_	JJ	_	_	_	_	_
9	comparison	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	medical	_	_	JJ	_	_	_	_	_
12	information	_	_	NN	_	_	_	_	_
13	requests	_	_	NNS	_	_	_	_	_
14	were	_	_	VBD	_	_	_	_	_
15	made	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	registered	_	_	VBN	_	_	_	_	_
19	sponsor	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	cobimetinib	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	vemurafenib	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	dabrafenib	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	trametinib	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	encorafenib	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	or	_	_	CC	_	_	_	_	_
32	binimetinib	_	_	NN	_	_	_	_	_
33	if	_	_	IN	_	_	_	_	_
34	any	_	_	DT	_	_	_	_	_
35	missing	_	_	VBG	_	_	_	_	_
36	data	_	_	NNS	_	_	_	_	_
37	were	_	_	VBD	_	_	_	_	_
38	identified	_	_	VBN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	data	_	_	NNS	_	_	_	_	_
3	sources	_	_	NNS	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	coBRIM	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	COMBI-v	_	_	NNP	_	_	_	_	_
9	trials	_	_	NNS	_	_	_	_	_
10	included	_	_	VBD	_	_	_	_	_
11	primary	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	secondary	_	_	JJ	_	_	_	_	_
14	publications	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	data	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	European	_	_	JJ	_	_	_	_	_
19	public	_	_	JJ	_	_	_	_	_
20	assessment	_	_	NN	_	_	_	_	_
21	reports	_	_	NNS	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	EPAR	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	U.S.	_	_	NNP	_	_	_	_	_
27	Food	_	_	NNP	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	Drug	_	_	NNP	_	_	_	_	_
30	Administration	_	_	NNP	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	FDA	_	_	NNP	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	medical	_	_	JJ	_	_	_	_	_
35	review	_	_	NN	_	_	_	_	_
36	documents	_	_	NNS	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	current	_	_	JJ	_	_	_	_	_
41	U.S.	_	_	NNP	_	_	_	_	_
42	prescribing	_	_	NN	_	_	_	_	_
43	information	_	_	NN	_	_	_	_	_
44	(	_	_	-LRB-	_	_	_	_	_
45	see	_	_	VB	_	_	_	_	_
46	Table	_	_	NNP	_	_	_	_	_
47	S5	_	_	NNP	_	_	_	_	_
48	,	_	_	,	_	_	_	_	_
49	which	_	_	WDT	_	_	_	_	_
50	illustrates	_	_	VBZ	_	_	_	_	_
51	the	_	_	DT	_	_	_	_	_
52	data	_	_	NN	_	_	_	_	_
53	sources	_	_	NNS	_	_	_	_	_
54	and	_	_	CC	_	_	_	_	_
55	cutoff	_	_	NN	_	_	_	_	_
56	dates	_	_	NNS	_	_	_	_	_
57	for	_	_	IN	_	_	_	_	_
58	COMBI-v	_	_	NNP	_	_	_	_	_
59	,	_	_	,	_	_	_	_	_
60	coBRIM	_	_	NNP	_	_	_	_	_
61	,	_	_	,	_	_	_	_	_
62	and	_	_	CC	_	_	_	_	_
63	COLUMBUS	_	_	NNP	_	_	_	_	_
64	trials	_	_	NNS	_	_	_	_	_
65	)	_	_	-RRB-	_	_	_	_	_
66	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	data	_	_	NN	_	_	_	_	_
3	sources	_	_	NNS	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	COLUMBUS	_	_	NNP	_	_	_	_	_
7	trial	_	_	NN	_	_	_	_	_
8	include	_	_	VBP	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	primary	_	_	JJ	_	_	_	_	_
11	publication	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	U.S.	_	_	NNP	_	_	_	_	_
14	prescribing	_	_	NN	_	_	_	_	_
15	information	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	Array	_	_	NNP	_	_	_	_	_
19	BioPharma	_	_	NNP	_	_	_	_	_
20	data	_	_	NNS	_	_	_	_	_
21	on	_	_	IN	_	_	_	_	_
22	file	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	efficacy	_	_	NN	_	_	_	_	_
3	outcomes	_	_	NNS	_	_	_	_	_
4	presented	_	_	VBN	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	PFS	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	objective	_	_	JJ	_	_	_	_	_
9	response	_	_	NN	_	_	_	_	_
10	rate	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	ORR	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	duration	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	response	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	DOR	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	per	_	_	IN	_	_	_	_	_
22	investigator	_	_	NN	_	_	_	_	_
23	assessment	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	OS	_	_	NNP	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	assessments	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	tumor	_	_	NN	_	_	_	_	_
6	response	_	_	NN	_	_	_	_	_
7	across	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	studies	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	performed	_	_	VBN	_	_	_	_	_
12	using	_	_	VBG	_	_	_	_	_
13	Response	_	_	NN	_	_	_	_	_
14	Evaluation	_	_	NN	_	_	_	_	_
15	Criteria	_	_	NNP	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	Solid	_	_	NNP	_	_	_	_	_
18	Tumors	_	_	NNPS	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	RECIST	_	_	CD	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	version	_	_	NN	_	_	_	_	_
23	1.1	_	_	CD	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	safety	_	_	NN	_	_	_	_	_
3	comparisons	_	_	NNS	_	_	_	_	_
4	were	_	_	VBD	_	_	_	_	_
5	made	_	_	VBN	_	_	_	_	_
6	using	_	_	VBG	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	adverse	_	_	JJ	_	_	_	_	_
9	event	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	any	_	_	DT	_	_	_	_	_
12	untoward	_	_	JJ	_	_	_	_	_
13	medical	_	_	JJ	_	_	_	_	_
14	occurrence	_	_	NN	_	_	_	_	_
15	regardless	_	_	RB	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	causal	_	_	JJ	_	_	_	_	_
18	relationship	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	adverse	_	_	JJ	_	_	_	_	_
22	drug	_	_	NN	_	_	_	_	_
23	reaction	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	noxious	_	_	JJ	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	unintended	_	_	JJ	_	_	_	_	_
28	responses	_	_	NNS	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	at	_	_	IN	_	_	_	_	_
31	least	_	_	JJS	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	reasonable	_	_	JJ	_	_	_	_	_
34	possibility	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	a	_	_	DT	_	_	_	_	_
37	causal	_	_	JJ	_	_	_	_	_
38	relationship	_	_	NN	_	_	_	_	_
39	)	_	_	-RRB-	_	_	_	_	_
40	data	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	adverse	_	_	JJ	_	_	_	_	_
3	event	_	_	NN	_	_	_	_	_
4	data	_	_	NNS	_	_	_	_	_
5	included	_	_	VBD	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	overall	_	_	JJ	_	_	_	_	_
8	summaries	_	_	NNS	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	comprising	_	_	VBG	_	_	_	_	_
11	all-grade	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	serious	_	_	JJ	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	grade	_	_	NN	_	_	_	_	_
17	3/4	_	_	CD	_	_	_	_	_
18	AEs	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	AEs	_	_	NN	_	_	_	_	_
22	leading	_	_	VBG	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	death	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	dose	_	_	NN	_	_	_	_	_
27	interruption/modification	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	discontinuation	_	_	NN	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	incidence	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	specific	_	_	JJ	_	_	_	_	_
37	all-grade	_	_	JJ	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	grade	_	_	NN	_	_	_	_	_
40	3/4	_	_	CD	_	_	_	_	_
41	AEs	_	_	NN	_	_	_	_	_
42	by	_	_	IN	_	_	_	_	_
43	individual	_	_	JJ	_	_	_	_	_
44	preferred	_	_	VBN	_	_	_	_	_
45	terms	_	_	NNS	_	_	_	_	_
46	per	_	_	IN	_	_	_	_	_
47	the	_	_	DT	_	_	_	_	_
48	MedDRA	_	_	NNP	_	_	_	_	_
49	dictionary	_	_	NN	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	All	_	_	DT	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	utilized	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	National	_	_	NNP	_	_	_	_	_
6	Cancer	_	_	NNP	_	_	_	_	_
7	Institute	_	_	NNP	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	NCI	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	Common	_	_	NNP	_	_	_	_	_
12	Terminology	_	_	NN	_	_	_	_	_
13	Criteria	_	_	NNP	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	Adverse	_	_	JJ	_	_	_	_	_
16	Events	_	_	NNS	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	CTCAE	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	assess	_	_	VB	_	_	_	_	_
22	severity	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	coBRIM	_	_	NNP	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	COMBI-v	_	_	NNP	_	_	_	_	_
5	trials	_	_	NNS	_	_	_	_	_
6	used	_	_	VBD	_	_	_	_	_
7	version	_	_	NN	_	_	_	_	_
8	4.0	_	_	CD	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	whereas	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	COLUMBUS	_	_	NNP	_	_	_	_	_
13	trial	_	_	NN	_	_	_	_	_
14	used	_	_	VBD	_	_	_	_	_
15	version	_	_	NN	_	_	_	_	_
16	4.03	_	_	CD	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	primary	_	_	JJ	_	_	_	_	_
3	source	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	data	_	_	NNS	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	adverse	_	_	JJ	_	_	_	_	_
8	drug	_	_	NN	_	_	_	_	_
9	reactions	_	_	NNS	_	_	_	_	_
10	was	_	_	VBD	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	available	_	_	JJ	_	_	_	_	_
13	U.S.	_	_	NNP	_	_	_	_	_
14	prescribing	_	_	NN	_	_	_	_	_
15	information	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	additional	_	_	JJ	_	_	_	_	_
3	adverse	_	_	JJ	_	_	_	_	_
4	event	_	_	NN	_	_	_	_	_
5	data	_	_	NNS	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	dabrafenib	_	_	NN	_	_	_	_	_
9	plus	_	_	CC	_	_	_	_	_
10	trametinib	_	_	NN	_	_	_	_	_
11	combination	_	_	NN	_	_	_	_	_
12	was	_	_	VBD	_	_	_	_	_
13	derived	_	_	VBN	_	_	_	_	_
14	from	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	COMBI-d	_	_	NNP	_	_	_	_	_
17	trial	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	cobimetinib	_	_	JJ	_	_	_	_	_
4	plus	_	_	CC	_	_	_	_	_
5	vemurafenib	_	_	NN	_	_	_	_	_
6	combination	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	coBRIM	_	_	NN	_	_	_	_	_
10	trial	_	_	NN	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	utilized	_	_	VBN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	COLUMBUS	_	_	NNP	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	utilized	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	source	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	additional	_	_	JJ	_	_	_	_	_
11	information	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	adverse	_	_	JJ	_	_	_	_	_
14	events	_	_	NNS	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	encorafenib	_	_	NN	_	_	_	_	_
18	plus	_	_	CC	_	_	_	_	_
19	binimetinib	_	_	NN	_	_	_	_	_
20	combination	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_

